📊 AUPH Key Takeaways
Investment Thesis
Aurinia demonstrates exceptional profitability with 101.5% net margin and 37.1% operating margin, driven by 20.4% revenue growth to $283.1M. The company maintains fortress-like balance sheet strength with 5.25x current ratio, zero debt, and robust free cash flow generation of $135.7M (47.9% FCF margin), though the extraordinary 4893% net income growth warrants verification for non-recurring items or one-time gains.
AUPH Strengths
- Exceptional profitability metrics: 101.5% net margin and 37.1% operating margin far exceed pharmaceutical sector averages
- Strong revenue growth of 20.4% YoY in competitive pharma sector
- Fortress balance sheet with zero debt, $80.2M cash, and 5.25x current ratio providing financial flexibility
- Outstanding cash generation with $135.7M operating cash flow and 47.9% FCF margin
- High return on equity (49.4%) and ROA (38.2%) indicating efficient capital deployment
- Minimal liquidity risk with 4.76x quick ratio and strong interest coverage of 42.3x
AUPH Risks
- Extraordinary net income increase of 4893% YoY suggests material one-time gains, asset sales, or tax benefits requiring audit trail verification
- Pharmaceutical sector faces regulatory, patent cliff, and drug development execution risks not fully captured in trailing data
- Net margin of 101.5% (exceeding 100%) is unsustainable and indicates potential data anomalies or accounting items requiring clarification
- Significant insider trading activity (16 Form 4 filings in 90 days) warrants monitoring for potential information asymmetries
- Limited visibility into R&D pipeline productivity and clinical trial success rates from provided fundamentals
- Missing gross margin data and capex information limits operational efficiency assessment
Key Metrics to Watch
- Verification of non-operating income/one-time gains explaining 4893% net income growth
- Gross margin expansion or maintenance with revenue scale
- Operating cash flow sustainability relative to reported net income
- Research and development spend trends and pipeline advancement
- Revenue composition by product line and geographic segment
- Insider trading patterns and insider holding trends
AUPH Financial Metrics
💡 AI Analyst Insight
The 47.9% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 5.25x current ratio provides a solid financial cushion.
AUPH Profitability Ratios
AUPH vs Healthcare Sector
How Aurinia Pharmaceuticals Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
AUPH Balance Sheet & Liquidity
AUPH 5-Year Financial Trend
5-Year Trend Summary: Aurinia Pharmaceuticals Inc.'s revenue has grown significantly by 465% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.54 indicates the company is currently unprofitable.
AUPH Growth Metrics (YoY)
AUPH Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $67.8M | $722.0K | $0.03 |
| Q2 2025 | $57.2M | $722.0K | $0.01 |
| Q1 2025 | $50.3M | -$10.7M | $-0.07 |
| Q3 2024 | $54.5M | $4.3M | $0.03 |
| Q2 2024 | $41.5M | $722.0K | $0.01 |
| Q1 2024 | $34.4M | -$10.7M | $-0.07 |
| Q3 2023 | $54.5M | -$9.0M | $-0.06 |
| Q2 2023 | $28.2M | -$11.5M | $-0.08 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
AUPH Capital Allocation
AUPH SEC Filings
Access official SEC EDGAR filings for Aurinia Pharmaceuticals Inc. (CIK: 0001600620)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 10, 2026 | 4 | xslF345X05/wk-form4_1773174347.xml | View → |
| Mar 3, 2026 | 4 | xslF345X05/form4-03032026_100309.xml | View → |
| Mar 3, 2026 | 4 | xslF345X05/wk-form4_1772572473.xml | View → |
| Mar 3, 2026 | 4 | xslF345X05/wk-form4_1772572450.xml | View → |
| Mar 3, 2026 | 4 | xslF345X05/wk-form4_1772572423.xml | View → |
❓ Frequently Asked Questions about AUPH
What is the AI rating for AUPH?
Aurinia Pharmaceuticals Inc. (AUPH) has an AI rating of BUY with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are AUPH's key strengths?
Exceptional profitability metrics: 101.5% net margin and 37.1% operating margin far exceed pharmaceutical sector averages. Strong revenue growth of 20.4% YoY in competitive pharma sector.
What are the risks of investing in AUPH?
Extraordinary net income increase of 4893% YoY suggests material one-time gains, asset sales, or tax benefits requiring audit trail verification. Pharmaceutical sector faces regulatory, patent cliff, and drug development execution risks not fully captured in trailing data.
What is AUPH's revenue and growth?
Aurinia Pharmaceuticals Inc. reported revenue of $283.1M.
Does AUPH pay dividends?
Aurinia Pharmaceuticals Inc. does not currently pay dividends.
Where can I find AUPH SEC filings?
Official SEC filings for Aurinia Pharmaceuticals Inc. (CIK: 0001600620) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AUPH's EPS?
Aurinia Pharmaceuticals Inc. has a diluted EPS of $2.07.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.